Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators), HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization Sunrock Biopharma SLStartup |
Active Organization Sunrock Biopharma SLStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous Cell Carcinoma of Head and Neck | Preclinical | CL | Sunrock Biopharma SLStartup | 10 Oct 2022 |
Triple Negative Breast Cancer | Preclinical | CL | Sunrock Biopharma SLStartup | 10 Oct 2022 |